Lantheus Holdings, Inc. revenue
Lantheus Holdings, Inc.'s revenue was $1.54bn in fiscal 2025, up 0.5% on the year before. Since fiscal 2013 ($284m) it has grown at a compound 15.1% a year. Over the last twelve months it was $1.56bn.
Revenue history
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284 | 302 | 293 | 302 | 331 | 343 | 347 | 339 | 425 | 935 | 1,296 | 1,534 | 1,542 | 1,556 |
| Growth on the year before | — | +6.3% | −2.7% | +2.9% | +9.8% | +3.6% | +1.2% | −2.3% | +25.3% | +119.9% | +38.6% | +18.3% | +0.5% | — |
| Gross profit | 77 | 126 | 136 | 138 | 162 | 175 | 175 | 139 | 188 | 582 | 710 | 988 | 942 | 936 |
| Gross margin | 27.3% | 41.6% | 46.2% | 45.6% | 48.9% | 50.9% | 50.3% | 40.9% | 44.1% | 62.2% | 54.7% | 64.4% | 61.1% | 60.1% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $1.5B | ▼ 1.1% |
| PYLARIFY | $989M | ▼ 6.5% |
| Radiopharmaceutical Oncology | $989M | ▼ 6.5% |
| Total Precision Diagnostics | $493M | ▲ 12.7% |
| Definity | $330M | ▲ 3.9% |
| Techne Lite | $86.8M | ▼ 9.1% |
| Strategic Partnerships and Other | $59.4M | ▲ 55.5% |
| Neuraceq | $51.4M | — |
| License and Royalty Revenues | $34M | ▲ 272.9% |
| Other Precision Diagnostics | $24.6M | ▲ 1.6% |
| Other Radiopharmaceutical Oncology | $0 | ▼ 100.0% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $1.5B | 94.6% | ▼ 1.7% |
| Outside the US | $82.7M | 5.4% | ▲ 68.1% |
From Lantheus Holdings, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Lantheus Holdings, Inc. | $1.56bn | 2.3% | 11.4% |
| Phibro Animal Health Corp | $1.52bn | 17.1% | 15.8% |
| Indivior Pharmaceuticals, Inc. | $1.37bn | 16.3% | — |
| Trulieve Cannabis Corp. | $1.14bn | -3.9% | -0.6% |
| Prestige Consumer Healthcare Inc. | $1.10bn | -1.4% | -0.7% |
| ANI Pharmaceuticals Inc | $978m | 30.9% | 34.6% |
Compare with peers
- Phibro Animal Health Corp revenue
- Indivior Pharmaceuticals, Inc. revenue
- Trulieve Cannabis Corp. revenue
- Prestige Consumer Healthcare Inc. revenue
- ANI Pharmaceuticals Inc revenue
Head to head: LNTH vs PAHCINDV vs LNTHLNTH vs TRLV
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies